ATE537841T1 - Öl-in-wasser-emulsion eines grippeimpstoffs - Google Patents

Öl-in-wasser-emulsion eines grippeimpstoffs

Info

Publication number
ATE537841T1
ATE537841T1 AT08736288T AT08736288T ATE537841T1 AT E537841 T1 ATE537841 T1 AT E537841T1 AT 08736288 T AT08736288 T AT 08736288T AT 08736288 T AT08736288 T AT 08736288T AT E537841 T1 ATE537841 T1 AT E537841T1
Authority
AT
Austria
Prior art keywords
oil
water emulsion
flu vaccine
flu
vaccine
Prior art date
Application number
AT08736288T
Other languages
English (en)
Inventor
William Ripley Ballou
Emmanuel Jules Hanon
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0707697A external-priority patent/GB0707697D0/en
Priority claimed from GB0711357A external-priority patent/GB0711357D0/en
Priority claimed from GB0712062A external-priority patent/GB0712062D0/en
Priority claimed from PCT/EP2007/060743 external-priority patent/WO2008043774A1/en
Priority claimed from GB0724651A external-priority patent/GB0724651D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Application granted granted Critical
Publication of ATE537841T1 publication Critical patent/ATE537841T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16251—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT08736288T 2007-04-20 2008-04-16 Öl-in-wasser-emulsion eines grippeimpstoffs ATE537841T1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0707697A GB0707697D0 (en) 2007-04-20 2007-04-20 Vaccine
GB0711357A GB0711357D0 (en) 2007-06-12 2007-06-12 Vaccine
GB0712062A GB0712062D0 (en) 2007-06-21 2007-06-21 Vaccine
PCT/EP2007/060743 WO2008043774A1 (en) 2006-10-12 2007-10-10 Vaccine comprising an oil in water emulsion adjuvant
GB0724651A GB0724651D0 (en) 2007-12-18 2007-12-18 Vaccine
PCT/EP2008/054614 WO2008128939A1 (en) 2007-04-20 2008-04-16 Oil-in-water emulsion influenza vaccine

Publications (1)

Publication Number Publication Date
ATE537841T1 true ATE537841T1 (de) 2012-01-15

Family

ID=39766893

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08736288T ATE537841T1 (de) 2007-04-20 2008-04-16 Öl-in-wasser-emulsion eines grippeimpstoffs

Country Status (21)

Country Link
US (4) US9452209B2 (de)
EP (2) EP2136837B1 (de)
JP (1) JP2010524883A (de)
KR (1) KR101188382B1 (de)
CN (2) CN105311629A (de)
AR (1) AR066405A1 (de)
AT (1) ATE537841T1 (de)
AU (1) AU2008240761B2 (de)
BR (1) BRPI0810015B1 (de)
CA (1) CA2683075C (de)
CO (1) CO6251369A2 (de)
CR (1) CR11122A (de)
DO (1) DOP2009000239A (de)
EA (1) EA024250B1 (de)
ES (1) ES2377761T3 (de)
IL (1) IL200859A (de)
MA (1) MA31381B1 (de)
PE (1) PE20090146A1 (de)
TW (1) TW200908994A (de)
WO (1) WO2008128939A1 (de)
ZA (1) ZA200906753B (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
JP4812942B2 (ja) * 1999-02-26 2011-11-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル ＣＧモチーフを含むオリゴヌクレオチドを用いるＮｅｉｓｓｅｒｉａ抗原殺菌活性の増強
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
US20100221284A1 (en) * 2001-05-30 2010-09-02 Saech-Sisches Serumwerk Dresden Novel vaccine composition
DE10144906B4 (de) 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
ES2585810T3 (es) * 2005-03-23 2016-10-10 Glaxosmithkline Biologicals S.A. Uso de un virus de la gripe y un adyuvante de emulsión de aceite en agua para inducir respuesta de células T CD4 y/o una respuesta de células B de memoria mejorada
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
US20090304742A1 (en) * 2005-11-04 2009-12-10 Novartis Vaccines And Diagnostics Srl Influenza vaccines with reduced amount of emulsion adjuvant
JP2009514838A (ja) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル 細胞培養物において増殖されたインフルエンザウイルスから調製された非ビリオン抗原を含むアジュバントワクチン
PL2043682T3 (pl) 2006-07-17 2014-09-30 Glaxosmithkline Biologicals Sa Szczepionka przeciw grypie
JP5230632B2 (ja) * 2006-10-12 2013-07-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 水中油型エマルジョンアジュバントを含むワクチン
TW200908994A (en) 2007-04-20 2009-03-01 Glaxosmithkline Biolog Sa Vaccine
EP2173376B1 (de) * 2007-08-02 2015-03-25 Biondvax Pharmaceuticals Ltd. Multimere multiepitop-influenza-impfstoffe
US8506966B2 (en) 2008-02-22 2013-08-13 Novartis Ag Adjuvanted influenza vaccines for pediatric use
WO2009155489A2 (en) 2008-06-19 2009-12-23 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
CN102159242A (zh) 2008-09-18 2011-08-17 诺华有限公司 疫苗佐剂组合
EP2942062A1 (de) * 2009-02-10 2015-11-11 Novartis AG Influenza-impfstoff-schemata für pandemie-assoziierte stämme
US9278126B2 (en) * 2009-02-10 2016-03-08 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
AU2015203072B2 (en) * 2009-02-10 2017-05-25 Seqirus UK Limited Influenza vaccine regimens for pandemic-associated strains
EP2424565A1 (de) 2009-04-27 2012-03-07 Novartis AG Adjuvantierte impfstoffe zum schutz vor grippe
US20110097418A1 (en) * 2009-05-29 2011-04-28 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
WO2011049448A1 (en) * 2009-10-21 2011-04-28 De Staat Der Nederlanden, Vert. Door De Minister Van Vws Methods for diagnosis of immune responses against viruses
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
CN102802662A (zh) 2010-03-18 2012-11-28 诺华有限公司 用于脑膜炎球菌血清组b的含佐剂疫苗
WO2011130652A2 (en) * 2010-04-15 2011-10-20 George Baer Compositions and methods for vaccinating humans and animals against enveloped viruses
CA2801149A1 (en) * 2010-06-01 2011-12-08 Novartis Ag Concentration of vaccine antigens without lyophilization
GB201009273D0 (en) * 2010-06-03 2010-07-21 Glaxosmithkline Biolog Sa Novel vaccine
EP2585106A1 (de) 2010-06-25 2013-05-01 Novartis AG Kombinationen aus meningokokken-faktor-h-bindenden proteinen
US10286056B2 (en) * 2011-01-27 2019-05-14 Glaxosmithkline Biologicals S.A. Adjuvant nanoemulsions with crystallisation inhibitors
US9303070B2 (en) * 2011-02-22 2016-04-05 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
WO2012116714A1 (en) * 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
US10183069B2 (en) 2011-03-21 2019-01-22 Altimmune Inc. Rapid and prolonged immunologic-therapeutic
JP2014532620A (ja) * 2011-10-20 2014-12-08 ノバルティス アーゲー 小児の初回免疫のためのアジュバント添加インフルエンザｂウイルスワクチン
JP5918870B2 (ja) * 2012-03-06 2016-05-18 クルセル ホランド ベー ヴェー インフルエンザに対する改善されたワクチン接種
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
JP6719388B2 (ja) * 2014-12-25 2020-07-08 テルモ株式会社 皮内投与インフルエンザワクチン組成物
PL3558351T3 (pl) * 2016-12-23 2022-03-21 Intervet International B.V. Szczepionka skojarzona dla świń
WO2018144438A1 (en) 2017-01-31 2018-08-09 Merck Sharp & Dohme Corp. Methods for production of capsular polysaccharide protein conjugates from streptococcus pneumoniae serotype 19f
EP3579787B1 (de) 2017-02-13 2024-09-11 Boehringer Ingelheim Vetmedica GmbH Flüssigkeitsapplikator zur abgabe von impfstoffen
KR102651043B1 (ko) 2017-10-30 2024-03-22 다케다 야쿠힌 고교 가부시키가이샤 지질-외피보유 바이러스의 불활성화를 위한 환경 친화적 세제
EP3917567A1 (de) * 2019-01-30 2021-12-08 GlaxoSmithKline Biologicals SA Öl-/tensidmischungen zur selbstemulgierung
US20220133875A1 (en) * 2019-02-28 2022-05-05 Novavax, Inc. Methods for preventing disease or disorder caused by rsv infection
PH12021552094A1 (en) * 2019-03-04 2022-05-30 Japan As Represented By Director General Of Nat Institute Of Infectious Diseases Method for preparing influenza ha split vaccine
CN114222817A (zh) * 2019-04-06 2022-03-22 艾尔特免疫公司 广泛且持久的流感疫苗
RU2740751C1 (ru) * 2019-08-28 2021-01-20 Общество с ограниченной ответственностью "Развитие БиоТехнологий" Способ получения тетравалентной субъединичной противогриппозной вакцины
AU2020380604A1 (en) * 2019-11-07 2022-06-09 Seqirus UK Limited Compositions and methods for producing a viral vaccine with reduced particle size
CN113827715B (zh) * 2020-06-23 2024-07-05 普莱柯生物工程股份有限公司 一种抗h7亚型和h5亚型禽流感病毒的疫苗组合物、及其制备方法和应用
JP2023538665A (ja) * 2020-08-24 2023-09-08 サノフィ パスツール インコーポレイテッド トコフェロール含有スクアレンエマルションアジュバントを有するｃｏｖｉｄ－１９ワクチン
EP4237121A1 (de) 2020-10-29 2023-09-06 Industrial Polymers and Chemicals, Inc. Luftfilter mit überwachung und inaktivierung von krankheitserregern
TW202333778A (zh) * 2021-10-08 2023-09-01 美商賽諾菲巴斯德公司 多價流感疫苗
CN115607681A (zh) * 2022-08-31 2023-01-17 华南理工大学 一种基于免疫活性高分子材料构建的肿瘤原位疫苗及其制备与应用
KR102901149B1 (ko) * 2022-09-05 2025-12-17 주식회사 차백신연구소 에멀전 제형의 면역증강제 조성물 및 이의 제조 방법

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3238190A (en) 1963-10-23 1966-03-01 Madaus & Co K G Fa Dr Aescin recovery
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
DD155875A1 (de) 1980-12-31 1982-07-14 Willy Nordheim Verfahren zur herstellung eines ballaststoffarmen inaktivierten influenzaimpfstoffes
US4454119A (en) 1981-06-29 1984-06-12 Mitsubishi Chemical Industries Limited Therapeutic agents
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
FI69639C (fi) 1982-07-02 1986-03-10 Orion Yhtymae Oy Preparat foer anvaendning vid klamydia-diagnostik
DD211444A3 (de) 1982-08-19 1984-07-11 Saechsisches Serumwerk Verfahren zur herstellung von influenza-impfstoffen
GB8300467D0 (en) 1983-01-08 1983-02-09 Wellcome Found Equine influenza
FI861417A0 (fi) 1985-04-15 1986-04-01 Endotronics Inc Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav.
DD300833A7 (de) 1985-10-28 1992-08-13 Saechsische Landesgewerbefoerd Verfahren zur herstellung von inaktivierten influenza-vollvirusimpfstoffen
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
JP2851288B2 (ja) 1987-06-05 1999-01-27 アメリカ合衆国 癌診断および管理における自己分泌運動性因子
EP0304578B1 (de) 1987-06-22 2001-10-24 Medeva Holdings Bv Hepatitis-B-Oberflächenantigen enthaltendes Peptid
DE3734306A1 (de) 1987-10-10 1989-04-27 Pfeiffer Erich Gmbh & Co Kg Austragvorrichtung fuer fliessfaehige medien
US5376369A (en) * 1987-11-03 1994-12-27 Syntex (U.S.A.) Inc. Vaccine adjuvant
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
GB8819209D0 (en) 1988-08-12 1988-09-14 Research Corp Ltd Polypeptide & dna encoding same
GB8821049D0 (en) 1988-09-08 1988-10-05 Health Lab Service Board Method & composition for treatment & prevention of viral infections
US4999403A (en) 1988-10-28 1991-03-12 Exxon Chemical Patents Inc. Graft polymers of functionalized ethylene-alpha-olefin copolymer with polypropylene, methods of preparation, and use in polypropylene compositions
ES2068989T3 (es) * 1989-02-04 1995-05-01 Akzo Nobel Nv Tocoles como adyuvante en vacunas.
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
ATE159031T1 (de) 1989-07-25 1997-10-15 Smithkline Biolog Antigene sowie verfahren zu deren herstellung
DE4005528C2 (de) 1990-02-22 1998-01-15 Pfeiffer Erich Gmbh & Co Kg Austragvorrichtung für Medien
US5969109A (en) * 1990-02-28 1999-10-19 Bona; Constantin Chimeric antibodies comprising antigen binding sites and B and T cell epitopes
US5149531A (en) * 1990-06-27 1992-09-22 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method of using cold-adapted live influenza virus vaccine as an antiviral agent against influenza
US5030115A (en) 1990-07-23 1991-07-09 Molex Incorporated Tired socket assembly with integral ground shield
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
GB9105992D0 (en) 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
AU2927892A (en) 1991-11-16 1993-06-15 Smithkline Beecham Biologicals (Sa) Hybrid protein between cs from plasmodium and hbsag
MA22842A1 (fr) 1992-03-27 1993-10-01 Smithkline Beecham Biolog Procede de preparation de compositions de vaccin.
AU6141094A (en) 1993-02-19 1994-09-14 Smithkline Beecham Biologicals (Sa) Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
US5776468A (en) 1993-03-23 1998-07-07 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
US5762939A (en) * 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
WO1995011700A1 (en) 1993-10-29 1995-05-04 Pharmos Corp. Submicron emulsions as vaccine adjuvants
WO1995014026A1 (en) 1993-11-17 1995-05-26 Laboratoires Om S.A. Glucosamine disaccharides, method for their preparation, pharmaceutical composition comprising same, and their use
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
WO1995022989A1 (en) 1994-02-24 1995-08-31 Micro-Pak, Inc. Vaccines containing paucilamellar lipid vesicles as immunological adjuvants
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
EP1167378B1 (de) 1994-07-15 2011-05-11 University of Iowa Research Foundation Immunomodulatorische Oligonukleotide
US5629052A (en) 1995-02-15 1997-05-13 The Procter & Gamble Company Method of applying a curable resin to a substrate for use in papermaking
CA2211995A1 (en) 1995-02-24 1996-08-29 Cantab Pharmaceuticals Research Limited Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
US20030133944A1 (en) 2001-04-05 2003-07-17 Smithkline Beecham Biologicals S.A. Vaccine composition against malaria
US5856462A (en) * 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
WO1998050567A1 (en) 1997-05-02 1998-11-12 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
DE69815692T2 (de) 1997-09-05 2004-04-29 Glaxosmithkline Biologicals S.A. Öl in wasser emulsionen mit saponinen
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
US7459524B1 (en) 1997-10-02 2008-12-02 Emergent Product Development Gaithersburg Inc. Chlamydia protein, sequence and uses thereof
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
DE69937343T2 (de) 1998-05-07 2008-07-24 Corixa Corp., Seattle Adjuvanszusammensetzung und methoden zu deren verwendung
WO1999064301A1 (fr) 1998-06-08 1999-12-16 Sca Emballage France Emballage a remise a plat rapide
WO2000000462A1 (fr) 1998-06-30 2000-01-06 Om Pharma Nouveaux pseudodipeptides acyles, leur mode de preparation et les compositions pharmaceutiques en renfermant
AT408615B (de) * 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
AT407958B (de) 1999-02-11 2001-07-25 Immuno Ag Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
ES2242604T3 (es) 1999-02-26 2005-11-16 Chiron Corporation Microemulsiones con macroparticulas y microparticulas adsorbidas.
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
US6494865B1 (en) 1999-10-14 2002-12-17 Becton Dickinson And Company Intradermal delivery device including a needle assembly
AU1581400A (en) 1999-12-22 2001-07-03 Om Pharma Acyl pseudopeptides bearing a functionalised auxiliary spacer
JP2003529559A (ja) 2000-01-31 2003-10-07 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規用途
GB0025577D0 (en) * 2000-10-18 2000-12-06 Smithkline Beecham Biolog Vaccine
EP1201250A1 (de) 2000-10-25 2002-05-02 SMITHKLINE BEECHAM BIOLOGICALS s.a. Immunogenische Zusammensetzung die hepatische Phaseantigene aus Plasmodium enthält
US20040071734A1 (en) 2001-02-23 2004-04-15 Nathalie Garcon Novel vaccine
WO2002085905A1 (en) 2001-04-17 2002-10-31 Sumitomo Pharmaceuticals Company, Limited Novel adenine derivatives
TWI228420B (en) 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
ES2318615T3 (es) 2001-11-16 2009-05-01 Coley Pharmaceutical Group, Inc. N-(4-(4-amino-2-etil-1h-imidazo(4,5-c)quinolin-1-il)butil)metanosulfonamida, una composicion farmaceutica que la comprende y uso de la misma.
US6861410B1 (en) * 2002-03-21 2005-03-01 Chiron Corporation Immunological adjuvant compositions
US20040074760A1 (en) * 2002-10-17 2004-04-22 Carnegie Mellon University Production of biofuels
JP4675317B2 (ja) 2003-01-30 2011-04-20 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド アジュバント化インフルエンザワクチン
EP1592302A4 (de) 2003-02-13 2007-04-25 3M Innovative Properties Co Verfahren und zusammensetzungen, die mit irm-verbindungen und dem toll-like rezeptor 8 in zusammenhang stehen
CN1522691A (zh) * 2003-09-05 2004-08-25 韦怀新 核酸、蛋白多肽及疫苗乳剂的制备方法
CA2559371C (en) 2004-03-09 2014-07-08 Chiron Corporation Influenza virus vaccines
US20090028903A1 (en) * 2005-03-23 2009-01-29 Glaxosmithkline Biologicals, S.A. Novel use
ES2585810T3 (es) * 2005-03-23 2016-10-10 Glaxosmithkline Biologicals S.A. Uso de un virus de la gripe y un adyuvante de emulsión de aceite en agua para inducir respuesta de células T CD4 y/o una respuesta de células B de memoria mejorada
AR054822A1 (es) 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante
US20090304742A1 (en) * 2005-11-04 2009-12-10 Novartis Vaccines And Diagnostics Srl Influenza vaccines with reduced amount of emulsion adjuvant
JP2009514838A (ja) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル 細胞培養物において増殖されたインフルエンザウイルスから調製された非ビリオン抗原を含むアジュバントワクチン
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
EP2422810B1 (de) * 2006-07-17 2014-10-22 GlaxoSmithKline Biologicals s.a. Influenzaimpfstoff
PL2043682T3 (pl) 2006-07-17 2014-09-30 Glaxosmithkline Biologicals Sa Szczepionka przeciw grypie
US20080014217A1 (en) * 2006-07-17 2008-01-17 Emmanuel Jules Hanon Influenza vaccine
JP5230632B2 (ja) * 2006-10-12 2013-07-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 水中油型エマルジョンアジュバントを含むワクチン
TW200908994A (en) 2007-04-20 2009-03-01 Glaxosmithkline Biolog Sa Vaccine
JP2011506290A (ja) 2007-12-06 2011-03-03 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム インフルエンザ組成物
CN102414188B (zh) * 2009-04-21 2015-05-27 陶氏技术投资有限公司 使用高效催化剂的获得并保持指定的环氧烷生产参数的改进方法

Also Published As

Publication number Publication date
PE20090146A1 (es) 2009-03-23
EA200901161A1 (ru) 2010-06-30
CN101678096A (zh) 2010-03-24
US9452209B2 (en) 2016-09-27
TW200908994A (en) 2009-03-01
IL200859A0 (en) 2010-05-17
US20180339037A1 (en) 2018-11-29
EP2136837B1 (de) 2011-12-21
KR101188382B1 (ko) 2012-10-08
DOP2009000239A (es) 2009-11-15
CR11122A (es) 2010-03-22
ZA200906753B (en) 2010-12-29
IL200859A (en) 2015-10-29
ES2377761T3 (es) 2012-03-30
CO6251369A2 (es) 2011-02-21
AU2008240761B2 (en) 2014-05-29
CA2683075C (en) 2015-11-10
KR20100009576A (ko) 2010-01-27
EP2455101A3 (de) 2013-04-24
EP2136837A1 (de) 2009-12-30
AR066405A1 (es) 2009-08-19
AU2008240761A1 (en) 2008-10-30
WO2008128939A1 (en) 2008-10-30
US10548969B2 (en) 2020-02-04
JP2010524883A (ja) 2010-07-22
CA2683075A1 (en) 2008-10-30
MA31381B1 (fr) 2010-05-03
US20100189741A1 (en) 2010-07-29
US20170246290A1 (en) 2017-08-31
US9597389B2 (en) 2017-03-21
BRPI0810015A2 (pt) 2014-10-14
EP2455101A2 (de) 2012-05-23
BRPI0810015B1 (pt) 2021-12-14
US20090136543A1 (en) 2009-05-28
CN105311629A (zh) 2016-02-10
US10016495B2 (en) 2018-07-10
EA024250B1 (ru) 2016-08-31

Similar Documents

Publication Publication Date Title
ATE537841T1 (de) Öl-in-wasser-emulsion eines grippeimpstoffs
IL269427B (en) Vaccine nanotechnology
DK2086582T3 (da) Vaccine omfattende en olie-i-vand-emulsionsadjuvans
IL257739A (en) Methods for detecting signatures of disease or conditions in bodily fluids
EP2484339A4 (de) Öl-in-wasser-emulsionszusammensetzung
SMT201600424B (it) Emulsione oftalmica
EP2127635A4 (de) Öl-in-wasser-emulsionszusammensetzung
BRPI0910205A2 (pt) respirador resistente a colapso
ATE450271T1 (de) Impfstoff
FR3016524B1 (fr) Interface comprenant une partie d'etancheite nasale
BRPI0816092A2 (pt) Máscara laríngea
HUE036174T2 (hu) Eljárások vakcina beadására
BR112012002231A2 (pt) emulsão óleo/água (o/w) espumável
EP2796126A4 (de) Öl-in-wasser-emulsionsverbindung
EP2318430A4 (de) Polyvalenter impfstoff
DK2114993T3 (da) Vaccine
DK2451887T3 (da) Emulsionsstabilisatorer til bore- og udbygningsfluider
CR10571A (es) Vacuna virica recombinante
BR112014009347A2 (pt) reguladores de fluido operados por piloto tendo um aparelho de restauração e métodos relacionados
EP2019687A4 (de) Impfstoff gegen streptokokken
BRPI0821034A2 (pt) Vírus influenza modificado
BRPI0817802A2 (pt) Dispersões aquosas
FR2956332B1 (fr) Dispositif d'application d'un fluide
DK2043682T3 (da) Influenzavaccine
IT1401736B1 (it) Dispositivo di perforazione per l'esecuzione di diaframmi e relativo metodo.